Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.10.19.345629v1?rss=1 Authors: Reva, B., Omelchenko, T., Calinawan, A. P., Nair, S., Schadt, E., Tewari, A. Abstract: We propose prioritization of prostate cancer patients to PD-L1 checkpoint therapy by assessing activity of IFN-gamma/PD-L1 signaling in tumor from transcriptional profile. To this end, we introduced a new approach for inferring pathway activity and suppression (IPAS) by assessing significance of positioning pathway's genes expression levels at top (activation) or bottom (suppression) in gene expression profile of a given tumor. By ordering tumors along IFN-gamma-PD-L1 axis, we determined distinct "IFN-gamma-depleted" and "IFN-gamma-enriched" immune subtypes, genes involved in immune evasion and potential targets for combination therapy. Using IPAS scoring method, we proposed biomarker panels for accurate ranking tumors along IFN-gamma/PD-L1 axis. Copy rights belong to original authors. Visit the link for more info